VLADIMIRHACHINSKIMD, FRCPC, DSC
THERE IS NO evidence to support the routine use of intravenous (IV) heparin in the treatment of any type of patient with acute ischemic stroke. The first randomized trial, undertaken by the Cerebral Embolism Study Group, stopped prematurely when there was a nonsignificant trend in favor of treatment, after only 45 (of a planned 140) patients with presumed cardioembolic stroke had been randomized.1Three years later, a randomized trial in 225 patients showed that there was no evidence of benefit from IV heparin in preventing stroke progression.2A quantitative systematic review of the data from these 2 trials also did not provide any evidence of net benefit.3
Sandercock P. Is There Still a Role for Intravenous Heparin in Acute Stroke? No. Arch Neurol. 1999;56(9):1160–1162. doi:10.1001/archneur.56.9.1160
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: